Page 39 - Read Online
P. 39

Page 16                    Conroy et al. Cancer Drug Resist 2021;4:543-58  https://dx.doi.org/10.20517/cdr.2021.07

                   KRAS-Mutant Cancers in Mouse Models and Patients. Cancer Discov 2020;10:54-71.  DOI  PubMed  PMC
               81.      Janne PA, al. E. KRYSTAL-1: Updated Safety and Efficacy Data With Adagrasib (MRTX849) in NSCLC With KRASG12C Mutation
                   From a Phase 1/2 Study. EORTC-NCI-AACR 32nd Symposium 2020; Oct 24-25.
               82.      Welsch ME, Kaplan A, Chambers JM, et al. Multivalent Small-Molecule Pan-RAS Inhibitors. Cell 2017;168:878-889.e29.  DOI
                   PubMed  PMC
               83.      Nakamura K, Ichise H, Nakao K, et al. Partial functional overlap of the three ras genes in mouse embryonic development. Oncogene
                   2008;27:2961-8.  DOI  PubMed
               84.      Hennig A, Markwart R, Esparza-Franco MA, Ladds G, Rubio I. Ras activation revisited: role of GEF and GAP systems. Biol Chem
                   2015;396:831-48.  DOI  PubMed
               85.      Freedman TS, Sondermann H, Friedland GD, et al. A Ras-induced conformational switch in the Ras activator Son of sevenless. Proc
                   Natl Acad Sci U S A 2006;103:16692-7.  DOI  PubMed  PMC
               86.      Jeng HH, Taylor LJ, Bar-Sagi D. Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis. Nat
                   Commun 2012;3:1168.  DOI  PubMed  PMC
               87.      Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD. Biochemical and Structural Analysis of Common
                   Cancer-Associated KRAS Mutations. Mol Cancer Res 2015;13:1325-35.  DOI  PubMed
               88.      Hofmann MH, Gmachl M, Ramharter J, et al. BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in
                   KRAS-Driven Cancers through Combined MEK Inhibition. Cancer Discov 2020.  DOI  PubMed  PMC
               89.      Shi ZQ, Yu DH, Park M, Marshall M, Feng GS. Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting
                   growth factor stimulation of Erk activity. Mol Cell Biol 2000;20:1526-36.  DOI  PubMed  PMC
               90.      Rauen KA. The RASopathies. Annu Rev Genomics Hum Genet 2013;14:355-69.  DOI  PubMed  PMC
               91.      Dance M, Montagner A, Salles JP, Yart A, Raynal P. The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase
                   (ERK1/2) pathway. Cell Signal 2008;20:453-9.  DOI  PubMed
               92.      Sun X, Ren Y, Gunawan S, et al. Selective inhibition of leukemia-associated SHP2 E69K  mutant by the allosteric SHP2 inhibitor
                   SHP099. Leukemia 2018;32:1246-9.  DOI  PubMed  PMC
               93.      Chen YN, LaMarche MJ, Chan HM, et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine
                   kinases. Nature 2016;535:148-52.  DOI  PubMed
               94.      De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with
                   chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010;304:1812-20.  DOI  PubMed
               95.      LoRusso PM, Sebolt-Leopold JS. One Step at a Time - Clinical Evidence That KRAS Is Indeed Druggable. N Engl J Med
                   2020;383:1277-8.  DOI  PubMed
               96.      Kim D, Xue JY, Lito P. Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients. Cell
                   2020;183:850-9.  DOI  PubMed  PMC
   34   35   36   37   38   39   40   41   42   43   44